Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:EXEL's Cash-to-Debt is ranked higher than
99% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:EXEL: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:EXEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.39 Max: No Debt
Current: No Debt
0.21
No Debt
Equity-to-Asset 0.39
NAS:EXEL's Equity-to-Asset is ranked lower than
83% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:EXEL: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:EXEL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.76  Med: 0.13 Max: 0.8
Current: 0.39
-0.76
0.8
Interest Coverage 7.97
NAS:EXEL's Interest Coverage is ranked lower than
91% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:EXEL: 7.97 )
Ranked among companies with meaningful Interest Coverage only.
NAS:EXEL' s Interest Coverage Range Over the Past 10 Years
Min: 5.51  Med: 5.51 Max: 5.51
Current: 7.97
Piotroski F-Score: 8
Altman Z-Score: 11.40
Beneish M-Score: -0.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 40.82
NAS:EXEL's Operating Margin % is ranked higher than
92% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:EXEL: 40.82 )
Ranked among companies with meaningful Operating Margin % only.
NAS:EXEL' s Operating Margin % Range Over the Past 10 Years
Min: -893.86  Med: -145.27 Max: 30.91
Current: 40.82
-893.86
30.91
Net Margin % 36.80
NAS:EXEL's Net Margin % is ranked higher than
88% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:EXEL: 36.80 )
Ranked among companies with meaningful Net Margin % only.
NAS:EXEL' s Net Margin % Range Over the Past 10 Years
Min: -1040.57  Med: -113.64 Max: 26.14
Current: 36.8
-1040.57
26.14
ROE % 119.83
NAS:EXEL's ROE % is ranked higher than
100% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:EXEL: 119.83 )
Ranked among companies with meaningful ROE % only.
NAS:EXEL' s ROE % Range Over the Past 10 Years
Min: -2156.15  Med: -136.81 Max: -76.29
Current: 119.83
-2156.15
-76.29
ROA % 26.38
NAS:EXEL's ROA % is ranked higher than
92% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:EXEL: 26.38 )
Ranked among companies with meaningful ROA % only.
NAS:EXEL' s ROA % Range Over the Past 10 Years
Min: -63.23  Med: -31.4 Max: 20.08
Current: 26.38
-63.23
20.08
ROC (Joel Greenblatt) % 1563.42
NAS:EXEL's ROC (Joel Greenblatt) % is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:EXEL: 1563.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:EXEL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6260.17  Med: -1065.04 Max: 766.96
Current: 1563.42
-6260.17
766.96
3-Year Revenue Growth Rate 65.00
NAS:EXEL's 3-Year Revenue Growth Rate is ranked higher than
90% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:EXEL: 65.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:EXEL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.3  Med: 2.3 Max: 65
Current: 65
-61.3
65
3-Year EBITDA Growth Rate -48.70
NAS:EXEL's 3-Year EBITDA Growth Rate is ranked lower than
93% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:EXEL: -48.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:EXEL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -48.7  Med: -6.25 Max: 17.9
Current: -48.7
-48.7
17.9
3-Year EPS without NRI Growth Rate -40.50
NAS:EXEL's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:EXEL: -40.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:EXEL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.1  Med: -8.45 Max: 16.1
Current: -40.5
-42.1
16.1
GuruFocus has detected 2 Warning Signs with Exelixis Inc NAS:EXEL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:EXEL's 30-Y Financials

Financials (Next Earnings Date: 2018-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

EXEL Guru Trades in Q4 2016

Joel Greenblatt 422,461 sh (+224.82%)
Steven Cohen Sold Out
Jim Simons 1,310,510 sh (-29.86%)
Paul Tudor Jones 25,973 sh (-47.40%)
» More
Q1 2017

EXEL Guru Trades in Q1 2017

Steven Cohen 100,000 sh (New)
Joel Greenblatt 924,289 sh (+118.79%)
Jim Simons 1,558,060 sh (+18.89%)
Paul Tudor Jones Sold Out
» More
Q2 2017

EXEL Guru Trades in Q2 2017

Lee Ainslie 188,010 sh (New)
Caxton Associates 9,200 sh (New)
Paul Tudor Jones 106,091 sh (New)
Jim Simons 2,439,110 sh (+56.55%)
Joel Greenblatt 1,072,961 sh (+16.09%)
Steven Cohen Sold Out
» More
Q3 2017

EXEL Guru Trades in Q3 2017

Steven Cohen 225,000 sh (New)
Ken Fisher 8,800 sh (New)
Jim Simons 3,798,660 sh (+55.74%)
Steven Cohen 100,000 sh (unchged)
Caxton Associates Sold Out
Lee Ainslie Sold Out
Joel Greenblatt 867,089 sh (-19.19%)
Paul Tudor Jones 68,880 sh (-35.07%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Reduce -19.19%0.07%$23.35 - $29.24 $ 28.005%867,089
Ken Fisher 2017-09-30 New Buy$23.35 - $29.24 $ 28.005%8,800
Joel Greenblatt 2017-06-30 Add 16.09%0.05%$18.32 - $24.9 $ 28.0033%1,072,961
Joel Greenblatt 2017-03-31 Add 118.79%0.14%$14.73 - $23.12 $ 28.0038%924,289
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:NKTR, NAS:ALKS, OCSE:GEN, NAS:BLUE, NAS:JAZZ, NAS:SGEN, NAS:NBIX, NAS:SAGE, HKSE:02269, NAS:UTHR, NAS:IONS, XKRX:128940, NAS:BIVV, NAS:ALNY, NAS:JUNO, XKRX:215600, HKSE:01530, BOM:532523, NAS:TECH, HKSE:01177 » details
Traded in other countries:EX9.Germany,
Headquarter Location:USA
Exelixis Inc is a part of the healthcare sector. As a biotechnology company, it develops small molecule therapies for the treatment of cancer.

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer as Cometriq and advanced renal cell carcinoma, or kidney cancer, as Cabometyx. Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma. The company has partnerships with larger pharmaceutical and biotech firms to develop its pipeline, including Bristol, Sanofi, and Merck.

Ratios

vs
industry
vs
history
PE Ratio 52.83
EXEL's PE Ratio is ranked lower than
85% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. EXEL: 52.83 )
Ranked among companies with meaningful PE Ratio only.
EXEL' s PE Ratio Range Over the Past 10 Years
Min: 7.53  Med: 50.01 Max: 1154
Current: 52.83
7.53
1154
Forward PE Ratio 39.68
EXEL's Forward PE Ratio is ranked lower than
79% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. EXEL: 39.68 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 52.83
EXEL's PE Ratio without NRI is ranked lower than
84% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. EXEL: 52.83 )
Ranked among companies with meaningful PE Ratio without NRI only.
EXEL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.53  Med: 50.01 Max: 1154
Current: 52.83
7.53
1154
Price-to-Owner-Earnings 48.53
EXEL's Price-to-Owner-Earnings is ranked lower than
68% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. EXEL: 48.53 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EXEL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.09  Med: 54.8 Max: 465.42
Current: 48.53
4.09
465.42
PB Ratio 34.70
EXEL's PB Ratio is ranked lower than
97% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. EXEL: 34.70 )
Ranked among companies with meaningful PB Ratio only.
EXEL' s PB Ratio Range Over the Past 10 Years
Min: 2.53  Med: 17.86 Max: 316.67
Current: 34.7
2.53
316.67
PS Ratio 20.97
EXEL's PS Ratio is ranked lower than
63% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. EXEL: 20.97 )
Ranked among companies with meaningful PS Ratio only.
EXEL' s PS Ratio Range Over the Past 10 Years
Min: 1.64  Med: 9.33 Max: 47.25
Current: 20.97
1.64
47.25
Price-to-Free-Cash-Flow 44.52
EXEL's Price-to-Free-Cash-Flow is ranked lower than
64% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. EXEL: 44.52 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EXEL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.33  Med: 31.84 Max: 63.76
Current: 44.52
3.33
63.76
Price-to-Operating-Cash-Flow 43.61
EXEL's Price-to-Operating-Cash-Flow is ranked lower than
72% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. EXEL: 43.61 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EXEL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.28  Med: 31.11 Max: 62.72
Current: 43.61
3.28
62.72
EV-to-EBIT 47.14
EXEL's EV-to-EBIT is ranked lower than
91% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. EXEL: 47.14 )
Ranked among companies with meaningful EV-to-EBIT only.
EXEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -173  Med: -4.7 Max: 206.9
Current: 47.14
-173
206.9
EV-to-EBITDA 46.83
EXEL's EV-to-EBITDA is ranked lower than
89% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. EXEL: 46.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
EXEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -177.8  Med: -5 Max: 200.5
Current: 46.83
-177.8
200.5
EV-to-Revenue 19.31
EXEL's EV-to-Revenue is ranked lower than
60% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. EXEL: 19.31 )
Ranked among companies with meaningful EV-to-Revenue only.
EXEL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 8.8 Max: 51.6
Current: 19.31
1.8
51.6
Current Ratio 4.32
EXEL's Current Ratio is ranked higher than
50% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. EXEL: 4.32 )
Ranked among companies with meaningful Current Ratio only.
EXEL' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.36 Max: 9.35
Current: 4.32
0.84
9.35
Quick Ratio 4.27
EXEL's Quick Ratio is ranked higher than
52% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. EXEL: 4.27 )
Ranked among companies with meaningful Quick Ratio only.
EXEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.36 Max: 9.35
Current: 4.27
0.84
9.35
Days Inventory 121.40
EXEL's Days Inventory is ranked higher than
52% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. EXEL: 121.40 )
Ranked among companies with meaningful Days Inventory only.
EXEL' s Days Inventory Range Over the Past 10 Years
Min: 165.84  Med: 352.5 Max: 471.76
Current: 121.4
165.84
471.76
Days Sales Outstanding 80.13
EXEL's Days Sales Outstanding is ranked higher than
64% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. EXEL: 80.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.51  Med: 33.29 Max: 80.54
Current: 80.13
4.51
80.54
Days Payable 171.73
EXEL's Days Payable is ranked higher than
87% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. EXEL: 171.73 )
Ranked among companies with meaningful Days Payable only.
EXEL' s Days Payable Range Over the Past 10 Years
Min: 365.72  Med: 872.79 Max: 3050.92
Current: 171.73
365.72
3050.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.30
EXEL's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. EXEL: -16.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -204.5  Med: -11.95 Max: -1.3
Current: -16.3
-204.5
-1.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 82.35
EXEL's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. EXEL: 82.35 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EXEL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.99  Med: 10.38 Max: 205.25
Current: 82.35
3.99
205.25
Price-to-Tangible-Book 47.30
EXEL's Price-to-Tangible-Book is ranked lower than
98% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. EXEL: 47.30 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EXEL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.46  Med: 10.35 Max: 437.86
Current: 47.3
2.46
437.86
Price-to-Median-PS-Value 2.25
EXEL's Price-to-Median-PS-Value is ranked lower than
86% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. EXEL: 2.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EXEL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.09 Max: 3.86
Current: 2.25
0.21
3.86
Price-to-Graham-Number 10.53
EXEL's Price-to-Graham-Number is ranked lower than
99% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. EXEL: 10.53 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EXEL' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.07  Med: 6.23 Max: 74.72
Current: 10.53
2.07
74.72
Earnings Yield (Greenblatt) % 2.12
EXEL's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. EXEL: 2.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EXEL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -74  Med: -15 Max: 17.1
Current: 2.12
-74
17.1

More Statistics

Revenue (TTM) (Mil) $409.99
EPS (TTM) $ 0.53
Beta2.49
Short Percentage of Float6.91%
52-Week Range $16.72 - 32.50
Shares Outstanding (Mil)295.85

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 440 565 806 1,135
EPS ($) 0.46 0.72 1.48 2.30
EPS without NRI ($) 0.46 0.72 1.48 2.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
46.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}